文献速递临床试验与 GCP流行病学与生物统计

IMPROD 双参数 MRI 在临床疑似前列腺癌男性中的验证:一项前瞻性多中心试验

Validation of IMPROD biparametric MRI in men with clinically suspected prostate cancer: A prospective multi-institutional trial.
PubMed 文献 · PLoS Med · 2019-06-03

该前瞻性多中心试验在芬兰 4 家机构纳入 364 例临床疑似前列腺癌男性,验证 IMPROD 双参数 MRI(bpMRI)对临床显著前列腺癌(SPCa)的诊断准确性;338 例完成试验,IMPROD bpMRI 对 SPCa 的准确率为 70%(113/161),阴性预测值为 95%(71/75,95%CI 87%-98%)。

要点

  • IMPROD bpMRI 对临床显著前列腺癌的阴性预测值为 95%(71/75,95%CI 87%-98%)。
  • 将活检限制在 IMPROD bpMRI 可疑(Likert 3-5 分)男性可减少 22%(75/338)的活检人数,但漏诊 4 例(3%,4/146)SPCa。
  • IMPROD bpMRI 平均采集时间 15 分钟,不使用直肠内线圈和静脉对比剂。

核心结论

  • 在这项前瞻性多中心临床试验中,IMPROD bpMRI 对临床疑似前列腺癌男性的临床显著前列腺癌显示出高阴性预测值。

研究设计与样本

  • 前瞻性多中心试验(NCT02241122),2015年2月1日至2017年3月31日在芬兰 4 家机构纳入 364 例临床疑似前列腺癌男性,338 例(338/364,93%)完成试验。
  • IMPROD bpMRI 平均采集时间 15 分钟,不使用直肠内线圈和静脉对比剂,包括 T2 加权成像和 3 次独立的扩散加权成像采集。
  • IMPROD bpMRI Likert 评分 3-5 分者行最多 2 个病灶的各 2 针靶向活检后行系统活检;Likert 评分 1-2 分者仅行系统活检。
  • 主要结局为 IMPROD bpMRI 对临床显著前列腺癌(Gleason 评分 ≥ 3+4,即 Gleason 分级组 2 级或更高)的诊断准确性。

主要发现

  • IMPROD bpMRI 对临床显著前列腺癌的准确率为 70%(113/161),阴性预测值为 95%(71/75)(95%CI 87%-98%)。
  • 将活检限制在 IMPROD bpMRI 可疑(Likert 3-5 分)男性可使接受活检人数减少 22%(75/338),但漏诊 4 例(3%,4/146)临床显著前列腺癌。

局限性

  • 主要局限性是研究队列中真实前列腺癌患病率的不确定性,因为部分男性尽管活检阴性仍可能患有前列腺癌。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Magnetic resonance imaging (MRI) combined with targeted biopsy (TB) is increasingly used in men with clinically suspected prostate cancer (PCa), but the long acquisition times, high costs, and inter-center/reader variability of routine multiparametric prostate MRI limit its wider adoption. METHODS AND FINDINGS: The aim was to validate a previously developed unique MRI acquisition and reporting protocol, IMPROD biparametric MRI (bpMRI) (NCT01864135), in men with a clinical suspicion of PCa in a multi-institutional trial (NCT02241122). IMPROD bpMRI has average acquisition time of 15 minutes (no endorectal coil, no intravenous contrast use) and consists of T2-weighted imaging and 3 separate diffusion-weighed imaging acquisitions. Between February 1, 2015, and March 31, 2017, 364 men with a clinical suspicion of PCa were enrolled at 4 institutions in Finland. Men with an equivocal to high suspicion (IMPROD bpMRI Likert score 3-5) of PCa had 2 TBs of up to 2 lesions followed by a systematic biopsy (SB). Men with a low to very low suspicion (IMPROD bpMRI Likert score 1-2) had only SB. All data and protocols are freely available. The primary outcome of the trial was diagnostic accuracy-including overall accuracy, sensitivity, specificity, negative predictive value (NPV), and positive predictive value-of IMPROD bpMRI for clinically significant PCa (SPCa), which was defined as a Gleason score ≥ 3 + 4 (Gleason grade group 2 or higher). In total, 338 (338/364, 93%) prospectively enrolled men completed the trial. The accuracy and NPV of IMPROD bpMRI for SPCa were 70% (113/161) and 95% (71/75) (95% CI 87%-98%), respectively. Restricting the biopsy to men with equivocal to highly suspicious IMPROD bpMRI findings would have resulted in a 22% (75/338) reduction in the number of men undergoing biopsy while missing 4 (3%, 4/146) men with SPCa. The main limitation is uncertainty about the true PCa prevalence in the study cohort, since some of the men may have PCa despite having negative biopsy findings. CONCLUSIONS: IMPROD bpMRI demonstrated a high NPV for SPCa in men with a clinical suspicion of PCa in this prospective multi-institutional clinical trial. TRIAL REGISTRATION: ClinicalTrials.gov NCT02241122.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Jambor I, Verho J, Ettala O, et al. Validation of IMPROD biparametric MRI in men with clinically suspected prostate cancer: A prospective multi-institutional trial. PLoS Med. 2019. PMID: 31158230. doi:10.1371/journal.pmed.1002813

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。